Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp122 | Endocrine Tumours | ECE2017

The natural history of adrenal incidentaloma – results from the international prospective multi-centre EURINE-ACT study

Bancos Irina , Chortis Vasileios , Lang Katharina , Prete Alessandro , Terzolo Massimo , Fassnacht Martin , Quinkler Marcus , Kastelan Darko , Vassiliadi Dimitra , Beuschlein Felix , Ambroziak Urszula , Sitch Alice , Deeks Jonathan , Arlt Wiebke

Background: Adrenal masses are discovered in 5% of abdominal imaging scans. Work-up aims at exclusion of malignancy and hormone excess. However, estimates of these risks derive from retrospective studies only, mostly small and with significant selection bias.Methods: Prospective multi-centre study (2011–2016) in 14 centres (11 countries) of the European Network for the Study of Adrenal Tumours (ENSAT) with prospective consecutive enrolment of patien...

ea0035p534 | Endocrine tumours and neoplasia | ECE2014

Role of metformin on recurrence-free survival in neuroendocrine tumors

Marciello Francesca , Modica Roberta , Marotta Vincenzo , Ramundo Valeria , Prete Michela Del , Buonomano Pasqualina , Carratu Anna Chiara , de Luca di Roseto Chiara , Picillo Ester , Colao Annamaria , Faggiano Antongiulio

Introduction: Recent data suggest that metformin has antineoplastic properties in different type of cancer. Effects of metformin have never been investigated in neuroendocrine tumors (NET).We aim to determine the role of metformine on recurrence-free survival (RFS) in NET patients.Materials and methods: A retrospective analysis was conducted comparing NET patients with recent diagnosis (<3 year) of diabetes mellitus (with HbA1c...

ea0032p115 | Calcium and Vitamin D metabolism | ECE2013

Cinacalcet in patients with primary hyperparathyroidism (PHPT): comparison between sporadic and MEN1 PHPT

Prete Michela Del , Marotta Vincenzo , Ramundo Valeria , Marciello Francesca , Carratu Anna Chiara , di Roseto Chiara De Luca , Esposito Raffaella , Di Sarno Antonella , Colao Annamaria , Faggiano Antongiulio

Introduction: PHPT is a common endocrine disease characterized by hypercalcemia and different degree of osteoporosis and nephrolithiasis. PHPT arises in the context of an inherited disease in 5% of cases. Multiple endocrine neoplasia type 1 (MEN1) is the commonest cause of inherited PHPT. The main therapeutic approach for PHPT is surgery, however many patients refuse or have contraindications for surgery while others, in particular those with MEN1 PHPT, have persistent/relapsi...

ea0032p520 | Endocrine tumours and neoplasia | ECE2013

Assessment of fatal events in patients with radio-active iodine (RAI)-refractory differentiated thyroid cancer responsive to treatment with sorafenib

Marotta Vincenzo , Del Prete Michela , Ramundo Valeria , Marciello Francesca , Di Sarno Antonella , Esposito Raffaella , Carratu Annachiara , de Luca di Roseto Chiara , Camera Luigi , Colao Annamaria , Faggiano Antongiulio

Introduction: Targeted therapy with the multi-kinase inhibitor sorafenib is effective for treatment of differentiated thyroid cancer (DTC) unresponsive to RAI. Although kinase-inhibitors (KIs) are usually well tolerated, severe and even fatal adverse events are reported. Aim of the study was to assess incidence and characteristics of fatal events in patients with RAI-refractory DTC responsive to treatment with sorafenib.Design: A retrospective analysis o...

ea0032p529 | Endocrine tumours and neoplasia | ECE2013

Familial malignant paraganglioma is long-term stabilized with the tyrosine-kinase inhibitor sunitinib

Ramundo Valeria , Marciello Francesca , Del Prete Michela , Marotta Vincenzo , Esposito Raffaella , Chiara Carratu Anna , de Luca di Roseto Chiara , Colao Annamaria , Faggiano Antongiulio

Introduction: Paragangliomas are neuroectodermal tumors that arise from adrenal medulla or extra-adrenal ganglia and are characterized by high vascularisation. A high rate of these tumours is genetically inherited. For malignant paragangliomas, chemo- and radio-therapy are potentially effective, but tumor response is of short duration and patient prognosis is quite poor. Sunitinib is a tyrosine-kinase inhibitor, targeting VEGFR1, -2, PDGFRα, -β, RET and c-Kit. Recent...

ea0032p541 | Endocrine tumours and neoplasia | ECE2013

Sequential use of the kinase-inhibitors sorafenib and sunitinib in a patient affected with pluri-metastatic iodine-refractory follicular thyroid carcinoma

Marotta Vincenzo , Ramundo Valeria , Marciello Francesca , Del Prete Michela , Di Sarno Antonella , Esposito Raffaella , Carratu Annachiara , de Luca di Roseto Chiara , Camera Luigi , Colao Annamaria , Faggiano Antongiulio

Introduction: Kinase-inhibitors (KIs) are effective for treatment of most aggressive endocrine cancers. The crucial point about treatment with KIs is that these agents are not curative and their effects are at best transitory and are always followed by a restoration of tumour growth and progression. Several retrospective and phase II studies demonstrated efficacy of both sorafenib and sunitib for treatment of iodine refractory differentiated thyroid cancer although results fro...

ea0032p1080 | Thyroid cancer | ECE2013

A single-center, open-label, phase II, proof-of-concept study with pasireotide long-acting release in patients with progressive medullary thyroid cancer: 6-month evaluation

Faggiano Antongiulio , Ferolla Piero , Vitale Giovanni , Del Prete Michela , Ramundo Valeria , Esposito Raffaella , Marotta Vincenzo , Marciello Francesca , Carratu Anna Chiara , Camera Luigi , Fonti Rosi , Colao Annamaria

Introduction: Medullary thyroid cancer (MTC) is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1,2,3 and sst5 coul...

ea0029p1575 | Thyroid (non-cancer) | ICEECE2012

Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study

Ramundo V. , Fonderico F. , Assanti A. , Marciello F. , Prete M. Del , Marotta V. , Lombardi G. , Misso C. , Marzano L. , Colao A. , Spiezia S. , Faggiano A.

Introduction: Percutaneous radiofrequency thermal ablation (RTA) is a new promising therapeutic approach to manage compressive thyroid nodules (TNs).Aim: To investigate effectiveness and safety of RTA in the treatment of compressive TNs in patients not receiving surgery or radioiodine.Study design: Forty patients (31–86 years) with compressive TNs were enrolled. Twenty-two patients had non-toxic TNs and 18 had toxic TNs and we...

ea0073pep1.5 | Presented ePosters 1: Adrenal and Cardiovascular Endocrinology | ECE2021

Modified-release hydrocortisone improves androgen excess and facilitates glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia: non-invasive monitoring in saliva and urine

Prete Alessandro , Baranowski Elizabeth S. , Lina Schiffer , Adaway Joanne E. , Hawley James M. , Keevil Brian G. , Porter John , Ross Richard J. , Arlt Wiebke

BackgroundStandard glucocorticoid (GC) therapy in classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OHD-CAH) is often inadequate in controlling adrenal androgen excess, leading to GC over-exposure and poor health outcomes. A novel modified-release formulation of hydrocortisone (MR-HC, Chronocort® Diurnal Ltd. UK) has been shown to improve circulating adrenal androgen excess in 21-OHD-CAH. We investigated whether saliva and ...

ea0092ps3-27-03 | Thyroid Cancer clinical 3 | ETA2023

A large series of patients with anaplastic thyroid cancer managed in a tertiary referral center

Minaldi Elisa , Sabini Elena , Prete Alessandro , Agate Laura , Bottici Valeria , Brogioni Sandra , Torregrossa Liborio , Ugolini Clara , Materazzi Gabriele , Ribechini Alessandro , Bruschini Luca , Molinaro Eleonora , Matrone Antonio , Elisei Rossella

Objectives: Anaplastic thyroid cancer (ATC) is one of the deadliest cancers, with a median overall survival (OS) of 4 months and a disease-specific mortality of ˜100%. Although to date no effective treatment can cure the disease, some anecdotal cases achieved longer survival and very rarely the cure of the disease. Multimodal treatment with surgery, radiotherapy, multikinase inhibitors (MKI) could improve survival in ATC, particularly when surgery is not feasible.<p c...